Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, such as STR assays for human ID, and assays for food contamination; PCR instruments include digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It also offers predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a collaboration with the U.S. FBI; and with Bio-Manguinhos/Fiocruz to detect malaria and dengue. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Qiagen NV

Mr. Thierry  Bernard

CEO, MD & Member of Management Board

Dr. Roland  Sackers

CFO, MD & Member of Management Board

Mr. Antonio  Santos

Senior VP & Head of Global Operations

Mr. John  Gilardi

Vice President of Corporate Communications & Investor Relations

Ms. Stephany  Foster

Senior VP & Head of Human Resources

Dr. Thomas  Schweins

Senior Vice President of Life Science Business Area

Dr. Thomas  Theuringer

Senior Director & Head of External Communications

Mr. Jean-Pascal  Viola

Senior VP & Head of Corporate Strategy and Business Development

Dr. Jonathan G. Sheldon Ph.D.

Senior VP & Head of the QIAGEN Digital Insights Business Area

Mr. Fernando  Beils

Senior VP & Head of the Molecular Diagnostics Business Area

QIA's next earnings is on April 30, 2025 (After Market Close)

QIA's latest dividend is 1.31959 EUR on January 29, 2024

Qiagen NV (QIA) Stock Analysis, Discussion Forum and Financial Metrics - XETRA Exchange

Qiagen NV (QIA) Earnings Report Date and History | XETRA

QIA's next earnings is on April 30, 2025 (After Market Close)

When is the earnings report for QIA?

QIA Earnings History

QIA's latest dividend is 1.31959 EUR on January 29, 2024

QIA Stock Discussion Forum and Message Board

News for XETRA: QIA